Research and Markets (http://www.researchandmarkets.com/research/bqfdcg/cardiovascular)
has announced the addition of the "Asia
Pacific Cardiovascular Diseases Therapeutics Market 2013-2019"
report to their offering.
The value of the CVD market in India, Australia, China and Japan
amounted to an estimated $7.61 billion in 2012, and is expected to grow
at a Compound Annual Growth Rate (CAGR) of 1.4% over the forecast period
to reach $8.39 billion in 2019
Asia Pacific Cardiovascular Diseases Therapeutics Market 2013-2019
provides insights into three cardiovascular therapeutic indications in
in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The
report provides an in-depth analysis of the cardiovascular therapeutic
indications, namelyheart failure, myocardial infarction (MI), acute
coronary syndrome (ACS).
The market for Cardiovascular Disease (CVD) - comprising heart failure,
myocardial infarction and Acute Coronary Syndrome (ACS) - has registered
modest growth from 2007-2012 the period due to the launch of various
blockbuster drugs. The market is expected to grow at a gradual rate over
the forecast period from 2012 to 2019, due to the patent expiry of a
number of blockbuster drugs, including Lipitor (atorvastatin) and Plavix
The report provides an estimation of market size for 2012, along with
market forecast until 2019. It also covers disease epidemiology,
treatment algorithms, treatment patterns, in-depth analysis of the
pipeline, and deal analysis for these three cardiovascular indications.
Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/bqfdcg/cardiovascular
[ Back To NFVZone's Homepage ]